MedTrace Logo

RLIP76 in Human Serum in Adults With Rheumatologic Diseases

NCT00861159 · Status: WITHDRAWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2011-01-12

No results posted yet for this study

Summary

It is the investigators aim to determine the feasibility of directly detecting anti-RLIP76 auto-antibodies in human serum using prepared RLIP76 antigen peptides in persons with rheumatologic disease and persons without rheumatologic diesease ("healthy subjects").

Conditions

  • Carotid Atherosclerosis

Sponsors & Collaborators

  • University of North Texas Health Science Center

    lead OTHER

Principal Investigators

  • Sanjay Awasthi, MD · University of North Texas Health Science Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00861159 on ClinicalTrials.gov